Cargando…
A mixed‐methods study of cyclin‐dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers
BACKGROUND: Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor targeted therapies dramatically improve survival outcomes for metastatic breast cancer (MBC), but they are associated with significant symptom burden that can impact patients’ health‐related quality of life (HRQOL) and treatment outcomes...
Autores principales: | Oswald, Laura B., Arredondo, Brandy, Kadono, Mika, Martinez‐Tyson, Dinorah, Meade, Cathy D., Penedo, Frank, Antoni, Michael H., Soliman, Hatem, Costa, Ricardo L. B., Jim, Heather S. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290228/ https://www.ncbi.nlm.nih.gov/pubmed/34165265 http://dx.doi.org/10.1002/cam4.4055 |
Ejemplares similares
-
Living with Metastatic Cancer: A Roadmap for Future Research
por: Tometich, Danielle B., et al.
Publicado: (2020) -
20 Years Later: Continued Relevance of Cancer, Culture, and Literacy in Cancer Education for Social Justice and Health Equity
por: Meade, Cathy D., et al.
Publicado: (2020) -
“I have cancer during COVID; that’s a special category”: a qualitative study of head and neck cancer patient and provider experiences during the COVID-19 pandemic
por: Kirtane, Kedar, et al.
Publicado: (2022) -
Epigenetically altered miR-193b targets cyclin D1 in prostate cancer
por: Kaukoniemi, Kirsi M, et al.
Publicado: (2015) -
Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway
por: Huang, Yun, et al.
Publicado: (2020)